

Maintenance treatment and therapeutic mechanisms of psoralen+UVA (PUVA) in patients with mycosis fungoides

Short title: PUVA and mycosis fungoides

PRINCIPAL INVESTIGATOR:

Peter Wolf, MD
Research Unit for Photodermatology
Department of Dermatology
Medical University of Graz
Auenbruggerplatz 8
A-8036 Graz, Austria
TEL +43/316/385-12371
FAX +43/316-385-12466
e-mail: peter.wolf@medunigraz.at
<http://www.medunigraz.at/bioimmuntherapie>

CO-INVESTIGATOR:

Mag. Dr. Ellen Heitzer
Department of Human Genetics
Medical University of Graz
Harrachgasse 21
8010 Graz
TEL +43/316/380-4116
FAX +43/316-380-9605
e-mail: ellen.heitzer@medunigraz.at

Project Summary:

PUVA therapy is a well-accepted first-line treatment option for skin-limited mycosis fungoides, leading to complete remission in 70 to 90% of treated patients. Long-term remissions can be achieved with PUVA. In a randomized multicenter trial we plan to investigate (1) the clinical efficacy of PUVA maintenance therapy and (2) the mechanisms by which PUVA leads to disease clearance in MF. Immunologic and oncogene analysis shall help establishing surrogate markers for predicting therapeutic response. A better understanding of the optimal regimen and the therapeutic mechanisms of PUVA in MF should help improving treatment strategies for this life-threatening disease. The understanding of the mode of action of PUVA in MF may also help to develop novel treatments using PUVA-affected pathways, allowing to achieve overall better long-term response and success.

Funding:

Supported by funds of the Oesterreichische Nationalbank (Anniversary Fund, project number: 15463)